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Overcoming a presumed differentiation block in the childhood muscle cancer embryonal rhabdomyosar-
coma is often thought to hold promise as an approach to replace cytotoxic chemotherapy with molecu-
larly-targeted differentiation therapies. In this issue of Cancer Cell, Tremblay and colleagues implicate
YAP1 and the Hippo signaling pathway in the maintenance of differentiation-arrested and proliferative
phenotypes for embryonal rhabdomyosarcoma.Differentiation therapy for the muscle
cancer rhabdomyosarcoma (RMS) has
been thought to hold promise for replac-
ing cytotoxic chemotherapy with mole-
cularly targeted therapies. Such a tar-
geted therapy might restore the terminal
myogenic differentiation program to the
rhabdomyosarcoma cells and (poten-
tially) reduce life-long chemotherapy
related sequelae for the patient. Indeed,
differentiation therapy has been used
successfully in the treatment of acute
promyelocytic leukemia and neuroblas-
toma (Reynolds and Lemons, 2001).
Embryonal rhabdomyosarcoma (ERMS),
an RMS subtype thought to have an
activated satellite cell phenotype and
an arrested myogenic differentiation
program, displays the greatest tendency
toward myodifferentiation and may be
amenable to differentiation therapy.
However, no successful differentiation
therapies for RMS have entered the clinic.
Recently, there has been renewed inter-
est in differentiation therapy for solid
tumors, the development of which will
depend on understanding the molecular
mechanisms involved in suppressing
differentiation and identifying targets for
therapeutics. In the work presented in
this issue of Cancer Cell, Tremblay et al.
(2014) implicate YAP1 and the Hippo
signaling pathway in the differentiation-
arrested and proliferative phenotypes of
ERMS.
Tremblay at al. (2014) first explored the
expression and cellular compartment
localization of YAP1 in human RMS
samples and found that YAP1 was over-
expressed in ERMS tumors and was154 Cancer Cell 26, August 11, 2014 ª2014 Epredominately nuclear localized. YAP1
immunostaining correlated with Ki-67
positivity. These results are in accord
with a recent report in which the YAP1
oncoprotein was found to be over-
expressed in both the cytoplasmic and
nuclear compartments in alveolar RMS
and ERMS tumor samples (Crose et al.,
2014). Furthermore, a number of patient-
derived ERMS samples also exhibited a
recurrent YAP1 locus copy number gain.
To examine the functional relevance
of these findings, Tremblay et al. (2014)
conditionally activated a doxycycline
(DOX)-inducible hYAP1 S127A transgene
to drive YAP1 overexpression in specific
lineages: Pax7-creERT2 (activated and
quiescent satellite cells), Myf5-Cre (pre-
natal and postnatal lineages of very early
myogenic progenitors/activated satellite
cells and early myoblasts), and Myod1-
iCre (early myogenic progenitors/acti-
vated satellite cells and early and late
myoblasts). Myf5-Cre also marks an adi-
pose lineage. Myf5-Cre and Myod1-iCre
mice developed ERMS-like tumors in the
interstitial compartment of all muscles.
These tumors demonstrated positive
desmin and myogenin immunostaining,
although no tumors developed in the
brown fat pads of Myf5-Cre mice. Pax7
mice whose limbs were cardiotoxin-
injured developed tumors arising from
the Pax7-creERT2 lineage; no tumors
developed in the contralateral uninjured
limbs of these mice, suggesting that
activated satellite cells and their progeny,
not the quiescent population, may be the
cell-of-origin in this YAP1-driven model
of ERMS.lsevier Inc.In this genetic system, the tumors were
transplantable—and yet this tumorigenc-
ity was reversible. Primary cell cultures
established from explant secondary
tumors were able to proliferate in the
presence of DOX, but spontaneously
differentiated when withdrawn from DOX
and subjected to low-serum culture con-
ditions. In vivo, mice bearing secondary
tumors experienced spontaneous regres-
sion and differentiation of their tumors
when withdrawn from DOX, demon-
strating that YAP1 overexpression drives
proliferation and may have a role in
arresting the terminal differentiation
program. It is perhaps not surprising
then that the genes preferentially down-
regulated following YAP1 normalization
included the early myogenic lineage
markers Pax7 and Myf5 with concomitant
upregulation of the differentiation markers
Myod1 and Myh4. Tremblay et al. (2014)
also found that YAP1 globally regulates
gene expression, maintaining the pro-
proliferation phenotype through direct
transcriptional repression of myogenic
regulatory factors and gene expression
upregulation of known inhibitors of
Myod1 and Mef2 (i.e., Id2, Twist1, and
Snai1/2). Correlatively, YAP1 expression
declines in differentiating mouse and
human fetal myoblasts.
It should be noted that murine primary
tumors in this model have only one
genetic lesion, and YAP1 overexpres-
sion is linked to not only the Rosa26
promoter, but also a tetracycline-res-
ponsive element, resulting in a perhaps
nonphysiological level of (over)ex-
pression. While Tremblay et al. (2014)
Figure 1. Benchmarking Myogenic Differentiation in Human ERMS
Representative interventions reported as percentage increase of MHC
positive cells in vitro or in vivo (Barlow et al., 2006; Chen et al., 2014; Puri
et al., 2000; Taulli et al., 2009; Wegorzewska et al., 2003). (In the case of
RAR, MHC was not done but the authors reported no differentiation by
morphology or by Troponin-T immunocytochemistry in response to retinoic
acid.) Corresponding targets are noted. For consistency, only studies of
the prototypic RD cell line (generated in 1968) are included. Some of these
pathways may be interlinked (e.g., GSK3b and YAP1 have been reported to
be coassociated on the Axin scaffold, regulating b-catenin and YAP1 signaling
in parallel). Illustration by Nick Escobar.
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YAP1 expression can be a
sufficient transformational
event in the murine myoblast
cell line C2C12, human
ERMS is more heteroge-
neous with a mutational
landscape known to be
considerably more complex
with multiple copy number
variants, a nonmodest back-
ground mutation rate, and
recurrent activating RAS mu-
tations (Shern et al., 2014).
The exact role of YAP1 in the
context of oncogenic RAS
signaling for ERMS is, as of
now, unexplored. However,
recent reports suggest that
YAP1 and KRAS converge
in other forms of cancer.
The same may be true in
ERMS, for which Tremblay
et al. (2014) provide evidence
that a YAP1 overexpressionsignature is associated with higher stage
tumors and worsened prognosis.
The most poignant result of these
studies was the attempt to translate
from a murine genetic proof-of-concept
system to a human tumor system, as
measured by the differentiation effect on
the human ERMS cell line RD in a xeno-
graft system. Knockdown of YAP1 in
overexpressing RD cells resulted in a
reduced tumorigencity, but only a 1.7%
increase in differentiation ability (and
overall, no more than a 3% differentiation
of tumor cells was seen). Thus, the revers-
ibility of YAP1 driven tumors was less
impressive in human RD tumor cells.
Unfortunately, too, only one human
ERMS cell culture was tested. The results
presented by Tremblay et al. (2014),
while novel and exciting, raise an impor-
tant question about the feasibility ofdifferentiation therapy: is complete dif-
ferentiation of nearly all ERMS cells within
a tumor really possible (Figure 1), if not
only in the setting of microscopic residual
disease? The authors suggest in their
Highlight that ‘‘YAP1 inhibition is a prom-
ising strategy for differentiation therapy
of ERMS.’’ We ask for caution on this
point. In the context of the mouse model
studies, their approach is interesting;
however, their experimental evidence is
insufficient and inadequate in the context
of a therapeutic strategy for human
patients. The same concern raised in
recent commentaries on the rigorousness
of preclinical studies (Macleod, 2014)
should be embraced here, so that unjusti-
fied clinical trials are not initiated—and
so that families of children affected by
ERMS are not given false hope. Nonethe-
less, one might say this approach isCancer Cell 26, August 11worthy of deeper study—
potentially bymeans of target-
ing several pathways simulta-
neously. We have known
since the earliest chemo-
therapy clinical trials that
combination therapies are
more effective than single
agents. In RMS, differentiation
therapy may be no different.
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